Context Therapeutics (CNTX) Stock Forecast & Price Target $2.60 +0.20 (+8.33%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.64 +0.04 (+1.54%) As of 05/22/2026 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Context Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 8 Analyst RatingsSell1Hold0Buy7 Based on 8 Wall Street analysts who have issued ratings for Context Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 1 has given a sell rating, 6 have given a buy rating, and 1 has given a strong buy rating for CNTX. Consensus Price Target $6.60153.85% Upside According to the 8 analysts' twelve-month price targets for Context Therapeutics, the average price target is $6.60. The highest price target for CNTX is $9.00, while the lowest price target for CNTX is $5.00. The average price target represents a forecasted upside of 153.85% from the current price of $2.60. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for CNTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Context Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTX Analyst Ratings Over TimeTypeCurrent Forecast5/24/25 to 5/24/261 Month Ago4/24/25 to 4/24/263 Months Ago2/23/25 to 2/23/261 Year Ago5/24/24 to 5/24/25Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)Buy6 Buy rating(s)7 Buy rating(s)7 Buy rating(s)3 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price Target$6.60$6.60$6.00$6.00Forecasted Upside153.85% Upside192.04% Upside163.16% Upside765.93% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyBuy CNTX Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History CNTX Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Context Therapeutics Stock vs. The CompetitionTypeContext TherapeuticsMedical CompaniesBroader MarketConsensus Rating Score 2.88 2.30 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside153.85% Upside1,714.95% Upside15.09% UpsideNews Sentiment RatingPositive NewsSee Recent CNTX NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails4/20/2026 Weiss RatingsNot Rated Reiterated RatingSell (D-)3/24/2026 D. Boral Capital3 of 5 starsJason Kolbert3 of 5 starsReiterated RatingBuy$9.00+185.71%3/24/2026 Guggenheim5 of 5 starsPaul JengNot RatedReiterated RatingBuy$5.00+56.05%3/24/2026 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBiren AminSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$4.00 ➝ $7.00+131.79%2/23/2026 Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong-Buy12/22/2025 JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSoumit RoySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$7.00+451.18%11/6/2025 HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEmily BodnarSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$4.00 ➝ $5.00+342.47%10/2/2025 Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLi WatsekSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOverweight4/29/2025 William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatt PhippsSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform1/8/2025 Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSilvan TuerkcanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-BuyRead this warning immediately (Ad)Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.Read Porter Stansberry's full breakdown and protect your wealth nowAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:08 PM ET. CNTX Forecast - Frequently Asked Questions What is Context Therapeutics' forecast for 2026? According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Context Therapeutics is $6.60, with a high forecast of $9.00 and a low forecast of $5.00. Should I buy or sell Context Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Context Therapeutics in the last twelve months. There is currently 1 sell rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CNTX shares. Does Context Therapeutics's stock price have much upside? According to analysts, Context Therapeutics's stock has a predicted upside of 153.85% based on their 12-month stock forecasts. Has Context Therapeutics been upgraded by Wall Street analysts recently? Over the previous 90 days, Context Therapeutics's stock had 1 upgrade by analysts. What analysts cover Context Therapeutics? Context Therapeutics has been rated by research analysts at D. Boral Capital, Guggenheim, Lifesci Capital, Piper Sandler, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Context Therapeutics more than its competitors? Analysts like Context Therapeutics more than other "medical" companies. The consensus rating for Context Therapeutics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how CNTX compares to other companies. Stock Forecasts and Research Tools Related Companies XNCR Stock Forecast EVMN Stock Forecast AMPH Stock Forecast LBRX Stock Forecast VOR Stock Forecast SPRY Stock Forecast BIOA Stock Forecast ANRO Stock Forecast DRUG Stock Forecast IVA Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Context Therapeutics RecommendationsWall Street ZenWeiss RatingsD. Boral CapitalGuggenheimPiper SandlerLifesci CapitalJonesTradingHC WainwrightCantor Fitzgerald This page (NASDAQ:CNTX) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredThis small stock could surge when SpaceX goes publicWhen SpaceX goes public, billions in capital won't just flow into one stock - it will flood the entire sector....NXT Wave Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
